Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10026139 | 1.00 | TACR3 (1.00) | TACR3 | |
| SCHEMBL6837063 | 0.93 | TACR3 (1.00) | TACR3 | |
| SCHEMBL1393950 | 0.93 | TACR3 (1.00) | TACR3 | |
| SCHEMBL10026140 | 0.91 | TACR3 (1.00) | TACR3 | |
| SCHEMBL1393922 | 0.91 | TACR3 (1.00) | TACR3 | |
| SCHEMBL7688769 | 0.90 | TACR3 (1.00) | TACR3 | |
| SCHEMBL327311 | 0.90 | TACR3 (1.00) | TACR3 | |
| SCHEMBL1394625 | 0.88 | TACR3 (1.00) | TACR3 | |
| SCHEMBL6837267 | 0.88 | TACR3 (1.00) | TACR3 | |
| SCHEMBL7670985 | 0.88 | TACR3 (0.91) | TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507535-B2 | Methyl-pyrrolidine ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-08-13 | — | — | US | claimed |
| US-20120010212-A1 | METHYL-PYRROLIDINE ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | claimed |
| EP-2590963-B1 | (3-METHYLPYRROLIDIN-3-YL)METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-8507535-B2 | Methyl-pyrrolidine ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2590963-A1 | (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004207-A1 | (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010212-A1 | METHYL-PYRROLIDINE ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010212-A1 | METHYL-PYRROLIDINE ETHER DERIVATIVES | OPRM1, OPRK1, OPRD1 | TACR3 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.